Advertisement

Journal of Gastroenterology

, Volume 49, Issue 12, pp 1567–1577 | Cite as

Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection

  • Mayumi Tokunaga
  • Hirofumi UtoEmail author
  • Kohei Oda
  • Masahito Tokunaga
  • Seiichi Mawatari
  • Kotaro Kumagai
  • Kouichi Haraguchi
  • Makoto Oketani
  • Akio Ido
  • Nobuhito Ohnou
  • Atae Utsunomiya
  • Hirohito Tsubouchi
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Human T-lymphotropic virus type 1 (HTLV-1) may worsen the clinical course of hepatitis C virus (HCV) infection. The aim of this study was to investigate whether HTLV-1 coinfection influences the clinical characteristics of patients with HCV infection.

Methods

This retrospective study included 523 consecutive patients from January 2001 to December 2010 with chronic liver disease due to HCV infection, in whom serum anti-HTLV-1 antibodies were examined. Among these patients, 265 were diagnosed with hepatocellular carcinoma (HCC).

Results

The seroprevalence of anti-HTLV-1 antibodies was significantly higher in patients with HCC (21.1 %) than those without HCC (10.5 %, P = 0.001). This significant difference was observed in female patients (29.5 vs. 8.5 %, P < 0.001), but not in male patients (16.5 vs. 12.9 %, P = 0.501). In multivariate analysis, anti-HTLV-1 antibody positivity was independently associated with HCC in female patients [odds ratio (OR), 5.029; 95 % confidence interval (95 % CI), 1.760–14.369; P = 0.003], in addition to age (≥65 years; OR, 10.297; 95 % CI, 4.322–24.533; P < 0.001), platelet count (<15 × 104/μL; OR, 2.715; 95 % CI, 1.050–7.017; P = 0.039), total bilirubin (≥1 mg/dL; OR, 3.155; 95 % CI, 1.365–7.292; P = 0.007), and total cholesterol (≤160 mg/dL; OR, 2.916; 95 % CI, 1.341–6.342; P = 0.007). In contrast, HTLV-1 coinfection was not associated with HCC in male patients, although age, alcohol consumption, platelet count, and albumin were independently associated with HCC.

Conclusions

HTLV-1 coinfection may contribute to the development of HCC in patients with chronic HCV infection, especially in females.

Keywords

HTLV-1 Risk factor Hepatitis C virus Hepatocellular carcinoma Coinfection 

Notes

Conflict of interest

H. Tsubouchi holds endowed faculty positions in research for HGF tissue repair and regenerative medicine, and has received funds from Eisai Co., Ltd. The other authors declare that they have no conflict of interest.

References

  1. 1.
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1996;8:324–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology. 2002;36:S1–2.PubMedCrossRefGoogle Scholar
  4. 4.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305.PubMedCrossRefGoogle Scholar
  6. 6.
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998;28:562–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011;26:1757–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Chuang SC, Lee YC, Hashibe M, et al. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1261–8.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Suruki R, Hayashi K, Kusumoto K, et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer. 2006;119:192–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res. 1989;49:226–8.PubMedGoogle Scholar
  15. 15.
    Arisawa K, Soda M, Endo S, et al. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer. 2000;85:319–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer. 1989;43:1061–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–2.PubMedCrossRefGoogle Scholar
  19. 19.
    Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet. 1994;343:213–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Mochizuki M, Tajima K, Watanabe T, et al. Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol. 1994;78:149–54.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Yoshida M, Seiki M, Yamaguchi K, et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984;81:2534–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109:559–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Nakashima K, Hayashi J, Hirata M, et al. Hepatitis C virus infection on Iki Island, Japan, an area endemic for human T-lymphotropic virus type-I. A preliminary study in patients at clinics or hospitals. J Epidemiol. 1994;4:17–23.CrossRefGoogle Scholar
  24. 24.
    Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia. 2000;6:677–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Sauleda S, Juarez A, Esteban JI, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology. 2001;34:1035–40.PubMedCrossRefGoogle Scholar
  28. 28.
    Kishihara Y, Furusyo N, Kashiwagi K, et al. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis. 2001;184:1114–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112–9.CrossRefGoogle Scholar
  30. 30.
    Okayama A, Maruyama T, Tachibana N, et al. Increased prevalence of HTLV-I infection in patients with hepatocellular carcinoma associated with hepatitis C virus. Jpn J Cancer Res. 1995;86:1–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Stuver SO, Okayama A, Tachibana N, et al. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer. 1996;67:35–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki. Japan. J Infect Dis. 2000;181:35–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Mueller N, Okayama A, Stuver S, et al. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:2–7.CrossRefGoogle Scholar
  34. 34.
    Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis. 1993;167:57–65.PubMedCrossRefGoogle Scholar
  35. 35.
    Arisawa K, Soda M, Akahoshi M, et al. Human T-cell lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic bomb survivors in Nagasaki, Japan. Cancer Sci. 2006;97:535–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Shembade N, Harhaj EW. Role of post-translational modifications of HTLV-1 Tax in NF-kappaB activation. World J Biol Chem. 2010;1:13–20.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Nagai M, Brennan MB, Sakai JA, et al. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood. 2001;98:1858–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Welles SL, Tachibana N, Okayama A, et al. Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status. Int J Cancer. 1994;56:337–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Hishizawa M, Imada K, Kitawaki T, et al. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol. 2004;125:568–75.PubMedCrossRefGoogle Scholar
  40. 40.
    Soguero C, Joo M, Chianese-Bullock KA, et al. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol. 2002;76:9345–54.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Yonkers NL, Rodriguez B, Milkovich KA, et al. TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol. 2007;178:4436–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhang J, Yamada O, Kawagishi K, et al. Up-regulation of hepatitis C virus replication by human T cell leukemia virus type I-encoded Tax protein. Virology. 2007;369:198–205.PubMedCrossRefGoogle Scholar
  43. 43.
    Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249–57.PubMedCrossRefGoogle Scholar
  44. 44.
    Karp DR, Shimooku K, Lipsky PE. Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem. 2001;276:3798–804.PubMedCrossRefGoogle Scholar
  45. 45.
    Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Takahashi M, Higuchi M, Makokha GN, et al. HTLV-1 Tax oncoprotein stimulates ROS production and apoptosis in T cells by interacting with USP10. Blood. 2013;122:715–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Akuta N, Suzuki F, Seko Y, et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;56:2134–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Kobayashi M, Suzuki F, Akuta N, et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596–605.PubMedCrossRefGoogle Scholar
  49. 49.
    Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology. 2009;50:393–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Hanaoka M, Kubo T, Saitoh A. Discrepancy between human T-cell lymphotropic virus type I screening test and confirmatory tests in non-endemic areas. J Obstet Gynaecol Res. 2012;38:793–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Meytes D, Schochat B, Lee H, et al. Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. Lancet. 1990;336:1533–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Mayumi Tokunaga
    • 1
    • 2
  • Hirofumi Uto
    • 1
    Email author
  • Kohei Oda
    • 1
  • Masahito Tokunaga
    • 1
    • 2
  • Seiichi Mawatari
    • 1
  • Kotaro Kumagai
    • 1
  • Kouichi Haraguchi
    • 1
    • 3
  • Makoto Oketani
    • 1
  • Akio Ido
    • 1
  • Nobuhito Ohnou
    • 4
  • Atae Utsunomiya
    • 2
  • Hirohito Tsubouchi
    • 5
  1. 1.Digestive and Lifestyle Diseases, Department of Human and Environmental SciencesKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan
  2. 2.Department of HematologyImamura Bun-in HospitalKagoshimaJapan
  3. 3.Department of HematologyNational Hospital Organization Kagoshima Medical CenterKagoshimaJapan
  4. 4.Department of HematologyIkeda HospitalKanoyaJapan
  5. 5.Department of HGF Tissue Repair and Regenerative MedicineKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan

Personalised recommendations